Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)

被引：0
|
作者：
Laux, L.
Devinsky, O.
Miller, I
Nabbout, R.
Zolnowska, M.
Wright, S.
Roberts, C.
机构：
来源：
ANNALS OF NEUROLOGY | 2018年 / 84卷
关键词：
Epilepsy; Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
47
引用
收藏
页码：S344 / S344
页数：1
相关论文
共 50 条
  • [21] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE)
    Thiele, Elizabeth
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Lawson, John
    Wheless, James
    NEUROLOGY, 2023, 100 (17)
  • [22] Long-term safety and efficacy of add-on cannabidiol (CBD) for seizures associated with tuberous sclerosis complex (TSC): 3-year results from GWPCARE6 open-label extension (OLE)
    Wheless, James
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Jansen, Floor E.
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Lawson, John
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [23] Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
    Patel, Anup D.
    Mazurkiewicz-Beldzinska, Maria
    Chin, Richard F.
    Gil-Nagel, Antonio
    Gunning, Boudewijn
    Halford, Jonathan J.
    Mitchell, Wendy
    Scott Perry, Michael
    Thiele, Elizabeth A.
    Weinstock, Arie
    Dunayevich, Eduardo
    Checketts, Daniel
    Devinsky, Orrin
    EPILEPSIA, 2021, 62 (09) : 2228 - 2239
  • [24] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [25] Long- term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE)
    Thiele, E.
    Bebin, E.
    Filloux, F.
    Jansen, F.
    Kwan, P.
    Loftus, R.
    Sahebkar, F.
    Sparagana, S.
    Lawson, J.
    Wheless, J.
    ANNALS OF NEUROLOGY, 2023, 94 : S53 - S53
  • [26] Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan
    Inoue, Yushi
    Ohtsuka, Yoko
    EPILEPSY RESEARCH, 2015, 113 : 90 - 97
  • [27] Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study
    Lai, Wyman W.
    Galer, Bradley S.
    Wong, Pierre C.
    Farfel, Gail
    Pringsheim, Milka
    Keane, Martin G.
    Agarwal, Anupam
    EPILEPSIA, 2020, 61 (11) : 2386 - 2395
  • [28] ELAMIPRETIDE IN THE MMPOWER-2 OPEN-LABEL EXTENSION TRIAL (OLE): LONG-TERM SAFETY AND TOLERABILITY
    Karaa, Amel
    Haas, Richard
    Goldstein, Amy
    Vockley, Gerard
    Cohen, Bruce
    MUSCLE & NERVE, 2018, 58 : S34 - S34
  • [29] Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia
    Kasper, S
    Brecher, M
    Fitton, L
    Jones, AM
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (05) : 281 - 289
  • [30] LONG-TERM SPARSENTAN TREATMENT IN FSGS IN THE DUET OPEN-LABEL EXTENSION (OLE)
    Trachtman, Howard
    Srivastava, Tarak
    Tesar, Vladimir
    Campbell, Kirk N.
    Rheault, Michelle N.
    Komers, Radko
    Murphy, Edward
    Prasad, Andy
    Gesualdo, Loreto
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S99 - S99
12345